STRATA Skin Sciences Future Growth

Future criteria checks 0/6

STRATA Skin Sciences is forecast to grow earnings and revenue by 35.5% and 2.6% per annum respectively while EPS is expected to grow by 38.9% per annum.

Key information

35.5%

Earnings growth rate

38.9%

EPS growth rate

Medical Equipment earnings growth	16.9%
Revenue growth rate	2.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 May 2024

Recent future growth updates

Recent updates

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

Earnings and Revenue Growth Forecasts

NasdaqCM:SSKN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	34	-6	N/A	6	2
12/31/2024	31	-10	N/A	-2	2
3/31/2024	33	-11	-4	-1	N/A
12/31/2023	33	-11	-6	-1	N/A
9/30/2023	35	-7	-6	-2	N/A
6/30/2023	36	-7	-6	-2	N/A
3/31/2023	37	-6	-6	-2	N/A
12/31/2022	36	-6	-5	-1	N/A
9/30/2022	35	-6	-4	0	N/A
6/30/2022	33	-6	-3	1	N/A
3/31/2022	31	-3	-3	1	N/A
12/31/2021	30	-3	-2	2	N/A
9/30/2021	28	-2	-2	1	N/A
6/30/2021	26	-3	-2	1	N/A
3/31/2021	22	-6	-1	2	N/A
12/31/2020	23	-4	0	2	N/A
9/30/2020	25	-4	N/A	3	N/A
6/30/2020	27	-4	0	3	N/A
3/31/2020	31	-3	0	2	N/A
12/31/2019	32	-4	-1	2	N/A
9/30/2019	31	-3	0	2	N/A
6/30/2019	31	-3	2	3	N/A
3/31/2019	31	-3	1	3	N/A
12/31/2018	30	-4	1	3	N/A
9/30/2018	31	-9	2	4	N/A
6/30/2018	30	-22	1	2	N/A
3/31/2018	31	-21	2	3	N/A
12/31/2017	32	-22	N/A	4	N/A
9/30/2017	30	-18	N/A	4	N/A
6/30/2017	31	-6	N/A	4	N/A
3/31/2017	30	-4	N/A	3	N/A
12/31/2016	31	-3	N/A	0	N/A
9/30/2016	33	-3	N/A	-1	N/A
6/30/2016	33	-14	N/A	-3	N/A
3/31/2016	26	-22	N/A	-5	N/A
12/31/2015	18	-28	N/A	-7	N/A
9/30/2015	9	-34	N/A	-10	N/A
6/30/2015	1	-24	N/A	-12	N/A
3/31/2015	1	-15	N/A	-14	N/A
12/31/2014	1	-16	N/A	-18	N/A
9/30/2014	1	-14	N/A	-19	N/A
6/30/2014	1	-19	N/A	-20	N/A
3/31/2014	0	-27	N/A	-20	N/A
12/31/2013	1	-26	N/A	-19	N/A
9/30/2013	1	-27	N/A	-21	N/A
6/30/2013	0	-25	N/A	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SSKN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SSKN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SSKN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SSKN's revenue (2.6% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: SSKN's revenue (2.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time

STRATA Skin Sciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 33%

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Price target decreased by 11% to US$3.60

Consensus EPS estimates fall by 32%

Forecast breakeven date moved forward to 2024

Recent updates

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

STRATA Skin Sciences, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 11% to US$3.60

STRATA Skin Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast breakeven date moved forward to 2024

STRATA Skin Sciences, Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne

First quarter 2023 earnings: EPS misses analyst expectations

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences Announces TheraClearX Product Demonstration at Inaugural Winter Clinical Conference

STRATA Skin Sciences, Inc. Revises Revenue Guidance for the Full Year 2022

STRATA Skin Sciences, Inc. Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2024

STRATA Skin Sciences, Inc. Reiterates Earnings Guidance for the Year 2022

STRATA Skin Sciences Receives Non-Compliance Letter from NASDAQ

STRATA Skin Sciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

STRATA Skin Sciences, Inc. Provides Revenue Guidance Full Year 2022

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

STRATA Skin Sciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Strata Skin Sciences Announces U.S. Commercial Launch of Theraclear®X Acne Therapy System

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Consensus forecasts updated

STRATA Skin Sciences, Inc. Names Michael E. Goodman as Head of International Sales

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

STRATA Skin Sciences, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$4.30

STRATA Skin Sciences, Inc. Appoints Patricia S. Walker to Its Board of Director

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum 1.0 and First Installation in the U.S

STRATA Skin Sciences, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.015 loss per share (vs US$0.037 loss in 3Q 2020)

Price target increased to US$4.80

Independent Director recently bought US$104k worth of stock

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.05 loss in 2Q 2020)

STRATA Skin Sciences, Inc. (NasdaqCM:SSKN) entered into a definitive agreement to acquire U.S. Dermatology Business of Ra Medical Systems, Inc. from Ra Medical Systems, Inc. (NYSEAM:RMED) for $3.7 million.

Price target increased to US$4.20

Independent Director Samuel Navarro has left the company

Consensus EPS estimates fall to -US$0.17

First quarter 2021 earnings released: US$0.072 loss per share (vs US$0.031 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.11 loss in FY 2019)

Strata Skin Sciences Announces Expanded Distribution Agreement in China with Wuhan Miracle Laser Systems, Inc

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

STRATA Skin Sciences, Inc. Announces Executive Changes

CEO, President & Director Dolev Rafaeli has left the company